These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 39393045

  • 1. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T.
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [Abstract] [Full Text] [Related]

  • 2. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T.
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [Abstract] [Full Text] [Related]

  • 3. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 4. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
    Butzkueven H, Kappos L, Spelman T, Trojano M, Wiendl H, Su R, Liao S, Hyde R, Licata S, Ho PR, Campbell N.
    Ther Adv Neurol Disord; 2021 Jul; 14():17562864211042458. PubMed ID: 34603507
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR.
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [Abstract] [Full Text] [Related]

  • 6. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, Ren Z, Muralidharan KK, Licata S, Gafson AR.
    Mult Scler; 2021 Dec; 27(14):2240-2253. PubMed ID: 33821693
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
    Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e591. PubMed ID: 31355324
    [Abstract] [Full Text] [Related]

  • 8. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T, Fox EJ, Lucas N, Muralidharan KK, Mikol D.
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, Tibung JT, Lucas N, Subramanyam M, Natalizumab Trial Principal Investigators.
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, Kister I, Foley J.
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [Abstract] [Full Text] [Related]

  • 11. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2).
    Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Domingo-Horne R, Toukam M, Nunn A, Maghzi AH, Kuhelj R, Lasky T.
    Neurol Ther; 2024 Oct; 13(5):1385-1401. PubMed ID: 39046635
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
    BMC Neurol; 2019 Jun 08; 19(1):116. PubMed ID: 31176355
    [Abstract] [Full Text] [Related]

  • 13. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
    Chang I, Muralidharan KK, Campbell N, Ho PR.
    J Clin Pharmacol; 2021 Mar 08; 61(3):339-348. PubMed ID: 32949472
    [Abstract] [Full Text] [Related]

  • 14. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H, Petersen ER, Olsson A, Hejgaard Laursen J, Bredahl Hansen M, Oturai AB, Soelberg Sørensen P, Bach Søndergaard H, Sellebjerg F.
    Mult Scler Relat Disord; 2024 Aug 08; 88():105701. PubMed ID: 38889559
    [Abstract] [Full Text] [Related]

  • 15. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, de Vries A, Ten Brinke A, van Oosten BW, Barkhof F, Teunissen CE, Uitdehaag BMJ, Rispens T, Killestein J.
    Neurology; 2020 Aug 11; 95(6):e745-e754. PubMed ID: 32690785
    [Abstract] [Full Text] [Related]

  • 16. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
    Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S.
    Neurol Neuroimmunol Neuroinflamm; 2020 May 04; 7(3):. PubMed ID: 32019768
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies.
    Penkov K, Bondarenko I, Saenko DV, Kulyaba Y, Guo J, Gong Y, Yamamoto N, Hotko YS, Boyko V, Fadeeva NV, Ursol GM, Ahn HK, Kislov NV, Shen CI, Davis C, Kowalski K, Michelon E, Pavlov D, Hirohashi T, Cho BC.
    Ther Adv Med Oncol; 2024 May 04; 16():17588359241274592. PubMed ID: 39281971
    [Abstract] [Full Text] [Related]

  • 18. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
    Gelissen LMY, Loveless S, Toorop AA, Howlett J, Loeff FC, Rispens T, Killestein J, Tallantyre EC, van Kempen ZLE.
    Mult Scler Relat Disord; 2024 Oct 04; 90():105796. PubMed ID: 39096666
    [Abstract] [Full Text] [Related]

  • 19. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators.
    Lancet Neurol; 2018 May 04; 17(5):405-415. PubMed ID: 29545067
    [Abstract] [Full Text] [Related]

  • 20. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan 04; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.